HUTCHMED (China) (HCM) vs IDEAYA Biosciences (IDYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
HUTCHMED (China) (HCM) has outperformed IDEAYA Biosciences (IDYA) over the past year, losing 5.6% versus a loss of 24.8%. Over five years, IDYA leads with a +7.3% price change compared with -62.4% for HCM. IDEAYA Biosciences is the larger company by market cap ($2.47 billion vs $2.30 billion), about 1.1 times the size.
HUTCHMED (China) converts more of its revenue into profit, with a net margin of 83.3% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HCM | IDYA |
|---|---|---|
| Share price | $13.22 | $25.56 |
| Market cap | $2.30B | $2.47B |
| 1-day change | -1.71% | -2.33% |
| YTD return | -0.83% | -26.06% |
| 1-year return | -5.57% | -24.80% |
| 5-year return | -62.42% | +7.35% |
| P/E ratio (TTM) | 132.20 | — |
| Forward P/E | 51.00 | — |
| EPS (TTM) | $0.10 | $-4.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $548.51M | $218.71M |
| Revenue growth (YoY) | -12.96% | +3024.43% |
| Net income (latest FY) | $456.91M | $-113.70M |
| Gross margin | 38.68% | — |
| Operating margin | -7.14% | -72.84% |
| Net margin | 83.30% | -51.99% |
| 52-week high | $16.33 | $42.68 |
| 52-week low | $9.77 | $25.46 |
| Distance from 52-week high | -19.04% | -40.11% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +59.91% | +98.32% |
| Average volume | 64.48K | 933.58K |
| Shares outstanding | 173.81M | 96.69M |
| Employees | 1,790 | 145 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HCM has outperformed IDYA by 19.2 percentage points over the past year.
- HUTCHMED (China) is more profitable, keeping 83.3 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs -12.96%).
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
HCM vs IDYA FAQ
Which is bigger, HUTCHMED (China) or IDEAYA Biosciences?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $2.47B compared with $2.30B for HUTCHMED (China) (HCM).
Which stock has performed better over the past year, HCM or IDYA?
HCM returned -5.57% over the past 12 months, compared with -24.80% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are HUTCHMED (China) and IDEAYA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.